Key facts
- Notable investors include Impact Assets, AIM-HI, Cornell University, Rose Ventures, This is Water.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Chiara Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Chiara Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Chiara Biosciences
Developer of small-molecule therapeutics designed for targeted protein degradation. The company uses a modular linker system to enable intracellular self-assembly of bifunctional degraders that engage E3 ligases and target proteins, offering oral bioavailability, central nervous system penetration, resistance to the hook effect, and compatibility with high-throughput combinatorial screening, enabling pharmaceutical researchers scalable and reusable drug discovery across internal and collaborative pipelines.
- Sector
- Healthcare
- HQ
- Greenwood Village, CO, United States
- Founded
- 2024
- Employees
- 7
- Website
- chiarabio.com/
- Ownership
- Privately Held (backing)
Chiara Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Chiara Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Chiara Biosciences in its N-PORT filings yet. We sweep new filings monthly.